By Fineline Cube 
LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29, 2025. This partnership aims to develop novel Myeloid Engager Therapeutics targeting specific pathways for the treatment of autoimmune diseases with high unmet medical needs.
Collaboration Terms
Under the agreement, LTZ Therapeutics will receive an upfront payment in the tens of millions of dollars and an equity investment from Eli Lilly. Additionally, LTZ Therapeutics is eligible for potential milestone payments across various stages of drug development, including preclinical, clinical, regulatory, and commercialization phases. Following the commercial launch of any approved products, tiered royalties based on net sales will also be provided to LTZ Therapeutics.-Fineline Info & Tech